|  |  |  |  |
| --- | --- | --- | --- |
| **First author**  **Supplement 1 Summary table for characteristics of included studies** | **Study design** | **Country** | **Study description and outcomes** |
| Dai et al [1] | Retrospective; multicenter | China | **Total number of COVID positive cancer patients:** 105(Pan cancer study)  **Comparator:** 536 age-matched non-cancer patients  **Study enrollment time period:** January 1, 2020, to February 24, 2020, from 14 hospitals in Wuhan, China.  **Median age**:64.00  **Male/female:**57/48  **Comorbidities:** Hypertension 30; Cardiovascular disease 12; Diabetes 7; Cerebrovascular disease 5; Chronic kidney disease 6; Chronic liver disease 7.  **Outcomes assessed:**  Death rates [OR, 2.34; 95% confidence interval (CI), (1.15–4.77); P = 0.03],  ICU admission [OR, 2.84; 95% CI (1.59–5.08); P < 0.01], Severe or critical symptom [OR, 2.79; 95% CI, (1.74–4.41); P < 0.01].  **Cancer subtypes:**  Lung cancer:22 (20.95%); Gastrointestinal cancer:13 (12.38%); Breast cancer: 11 (10.48%); Thyroid cancer :11 (10.48%); Hematologic cancer:9 (8.57%).  **Cancer specific mortality rates:**  Hematologic cancer including leukemia, lymphoma, and myeloma highest death rate n=9: Death rate [3 (33.33%)] ; ICU admission rate [4 (44.44%)]; severe/critical symptoms [6 (66.67%)], and Utilization of invasive mechanical ventilation [2 (22.22%)].  Lung cancer n=22: Death rate [4 (18.18%)], ICU admission rate [6 (27.27%)], risks of severe/critical symptoms [11 (50.00%)] and utilization of invasive mechanical ventilation [4 (18.18%)].  Metastatic cancer (stage IV) had even higher risks of death [OR, 5.58; 95% CI (1.71–18.23); P = 0.01], ICU admission [OR, 6.59; 95% CI (2.32–18.72);  P < 0.01], having severe conditions [OR, 5.97; 95% CI (2.24– 15.91); P < 0.01], and use of invasive mechanical ventilation  **Cancer Treatments**  13 (12.26%) had radiotherapy, 17 (14.15%) received chemotherapy, 8 (7.62%) received surgery, 4 (3.81%) had targeted therapy, and 6 (5.71%) had immunotherapy within 40 days before the onset of COVID-19 symptoms.  Targeted drugs were EGFR–tyrosine kinase inhibitors for treatment of lung cancer, and all of the immunotherapy drugs were PD-1 inhibitors for the treatment of lung cancer.  **Treatment specific death rates**:  Immunotherapy: High rates of death [2 (33.33%) of 6 patients] and high chances of developing critical symptoms [4 (66.67%) of 6 patients].  Surgery: Death [2 (25.00%) of 8 patients], ICU admission [3 (37.50%) of 8 patients], severe or critical symptoms [5 (62.50%) of 8 patients], invasive ventilation [2 (25.00%) of 8 patients].  Radiotherapy: No significant differences in having any severe events. |
| He et al [2] | Retrospective; multicenter | China | **Total number of COVID positive cancer patients**: 13(hematological malignancies alone)  **Comparator:** 115 hematological COVID negative cancer patients  **Study enrollment time period**: January 23, 2020, to February 14, 2020  **Median age**:35 years  **Male/female**:7/6  **Comorbidities:** Cardiovascular disease and Cerebrovascular disease:3  **Outcomes assessed:**  Death rate: 8 subjects with hematological cancers and COVID19 died.  Need for mechanical ventilation:1/13  **Cancer subtypes:**  Acute myeloid leukemia: 4; Acute lymphoblastic leukemia 5; Plasma cell myeloma 3; Myelodysplastic syndromes 1 |
| Hogan et al[3] | Retrospective; multicenter | UK | **Total number of COVID positive cancer patients**: 26 (Admitted in 4 North London hospitals)  **Comparator:** 26 non-cancer COVID positive patients  **Study enrolment time period:** March 12 2020 to April 7 2020  **Median age**  Cancer patients: 76 years (IQR: 72 – 78)  Non-cancer patients: 58 years (IQR: 52 – 77)  **Male female ratio**  Cancer patients: 15/26 (58% males)  Non-cancer patients: 16/26 (62% males)  **Co-morbidities:** Atleast 1 co-morbidity in all patients  **Outcomes assessed:** Median hospital stay; Patients requiring ventilatory support; Mortality rates of cancer and non-cancer patients; Cancer specific mortality rate  **Cancer subtypes:** Colorectal cancer: 5 patients; Prostate cancer: 5 patients; Others: 16 patients  **Cancer Treatments:** 12 of 26 patients had received chemotherapy; 7 of 26 patients received targeted therapy; 1 patient received radiotherapy; 1 patient had undergone surgery; No patient received immunotherapy; 16 patients (62%) had received anti-cancer treatment within 4 weeks of admission  **Outcomes:** The median hospital stay for patients in both cohorts 7 days. No cancer patient admitted to ITU or treated with invasive ventilation. 12% (3/26) of cancer patients received non-invasive ventilatory support, all of whom died. Overall, 6 cancer patients 6 non-cancer patients died  **Cancer specific mortality rates:**  4 of 5 prostate cancer patients died, 1 pancreatic and 1 extensive small cell lung cancer patient died  **Treatment specific death rates:**  50% (3/6) patients who died received chemotherapy, and 50% (3/6) patients who died received targeted treatment |
| Jing et al [4] | Retrospective; single center | China | **Total number of COVID positive cancer patients**: 12  **Comparator:** Cancer patients without COVID infection (n = 1512); Infection rate: 0.79% (95% CI: 0.3 – 1.2%)  **Study enrolment time period:** December 30 2019 to February 17 2020  **Median age of COVID positive patients:** 66 years (Range: 48 – 78 years)  **Male female ratio**  **Co-morbidities:**  **Outcomes assessed:** Severe COVID 19 infection rate, mortality rate; Duration of hospitalization  **Cancer subtypes:** 7 of 12 patients were non-small cell lung cancer; 2 colo-rectal cancer patients; 1 each pancreatic, breast and urothelial cancer  **Cancer Treatments:** 5 patients received chemotherapy; 2 patients received immunotherapy and 3 patients received radiotherapy; 1 patient underwent surgery;  **Outcomes:** 3 of 12 patients died  **Cancer specific mortality rates:** 2 of 7 NSCLC died; 1 of 1 pancreatic cancer died  **Treatment specific death rates:** 1 patient on chemoradiotherapy, 1 patient on follow up after treatment and 1 patient on best supportive care died |
| Liang et al [5] | Retrospective, cancer database china | China | **Total number of COVID positive cancer patients**: 18  **Comparator:** 1572 non-cancer COVID positive patients  **Study enrolment time period:** Data cut-off date: January 31 2020  **Mean age:**  Cancer patients: 63.1 years (SD: 12.1 years)  Non-cancer patients: 48.7 years (SD: 16.2 years)  **Outcomes assessed:** Risk of severe events (composite endpoint defined as the percentage of patients being admitted to the intensive care unit  requiring invasive ventilation, or death), mortality rates; Time to severe event occurrence;  **Cancer subtypes:** 5 (28%) patients lung cancer  **Cancer Treatments:** 2 patients unknown treatment status; 4 (25%) patients on active cancer treatment with chemotherapy or surgery; 12 (75%) patients were cancer survivors on follow up after resection  **Outcomes:**  Patients with cancer were observed to have a higher risk of severe events compared with patients without cancer (9 [50%] of 18 patients *vs* 245 [16%] of 1572 patients; Fisher’s exact p=0.0008)  Patients with cancer deteriorated more rapidly than those without cancer (median time to severe events 13 days [IQR 6–15] *vs* 43 days [20–not reached]; p<0.0001;  **Cancer specific outcomes:**  Patients with lung cancer did not have a higher probability of severe events compared with patients with other cancer types (1 [20%] of 5 patients with lung cancer *vs* 8 [62%] of 13 patients with other types of cancer; p=0.294)  **Treatment specific outcomes:**  Patients who underwent chemotherapy or surgery in the past month had a numerically higher risk (3 [75%] of 4 patients) of clinically severe events than did those not receiving chemotherapy or surgery (6 [43%] of 14 patients) |
| Luo et al [6] | Retrospective; single center | USA | **Total number of COVID positive cancer patients**: 69 (Lung cancer patients alone; 41 patients received immunotherapy (PD1 blockade)); 80% (55/69) had active or metastatic lung cancer  **Comparator:** 28 patients who did not receive PD 1 blockade  **Study enrolment time period:** March 12 2020 to April 13 2020  **Median age:** 69 (Range 31- 91)  **Male female ratio**  48% (33/69) were males and 52% (36/69) were female  **Co-morbidities:** COPD 12/69 (17%); Non COPD lung disease 14/69 (20%); Obesity 23/69 (33%); Hypertension 38/69 (55%); Diabetes mellitus 21/69 (30%); Congestive heart failure 5/69 (7%)  **Outcomes assessed:** Mortality rate; rate of hospitalization; rate of severe disease a composite of ICU/intubation/transition to DNI-status;  **Cancer subtypes:** All lung cancer; 64 NSCLC; 5 SCLC  **Cancer Treatments:** 41 patients received PD1 blockade  **Outcomes:** Mortality rate: 16/67 (24%); rate of severe disease a composite of ICU/intubation/transition to DNI-status: 24/65 (37%); Rate of hospitalization: 42/67 (63%)  **Treatment specific outcomes:**  The odds ratios for the impact of PD-1 blockade on hospitalization, ICU/intubation/DNI, and death diminished to 1.20 (95% CI, 0.33 to 4.23), 0.83 (95% CI, 0.24-2.82), and 1.13 (95% CI, 0.25-5.03) |
| Mehta et al [7] | Retrospective; single center | USA | **Total number of COVID positive cancer patients**: 218  **Comparator:**  Age and sex-matched cohort of 1090 patients at a 5:1 ratio of non-cancer to cancer COVID-19 patients from the same time period and from the same hospital system  **Study enrolment time period:** March 18 2020 to April 8 2020  **Median age:** 69 years (Range 10 – 92 years)  **Male female ratio:** 127 (58%) males and 91 (42%) females  **Co-morbidities:** Diabetes mellitus: 80 patients; Hypertension: 147; Chronic lung disease: 62 patients; Chronic kidney disease: 54 patients  **Outcomes assessed:** Mortality rate; Cancer specific mortality rates; Treatment specific mortality rates  **Cancer subtypes:** Genito-urinary: 39 patients; Breast: 24 patients; Colorectal: 13 patients; Gynecologic: 8 patients; Lung: 5 patients; Head and neck: 7 patients; Neuro: 7 patients; Hematologic: 34 patients  **Cancer Treatments:** Radiation: 49 patients; Immunotherapy: 5 patients; Chemotherapy: 42 patients;  **Outcomes:**  61 of 218 cancer (28%) patients expired.  **Cancer specific mortality rates:**  The mortality was 25% of all solid tumor patients and was seen to occur at higher rates in lung cancers (55%), gastrointestinal cancers (colorectal (38%), pancreas (67%), upper GI (38%)) and gynecologic malignancies (38%). Hematologic malignancies were associated with higher rate of mortality with COVID-19 (37%). Active disease (< 1 year) and advanced metastatic disease showed a trend for increased mortality, but the association did not achieve statistical significance (p = 0.09 and 0.06, respectively).  **Treatment specific death rates:**  Active chemotherapy and radiation therapy treatment were not associated with increased case fatality. Very few patients in this cohort were on immunotherapy, and did not show any associations with mortality. |
| Miyashita et al[8] | Retrospective; single center | USA | **Total number of COVID positive cancer patients**: 334  **Comparator:** 5354 non-cancer patients  **Study enrolment time period:** March 1 2020 to April 6 2020  **Outcomes assessed:** Mortality rate; Intubation rate  **Cancer subtypes:** Breast: 57 patients; Prostate: 56 patients; Lung: 23 patients; urothelial: 18 patients; Colon cancer: 16 patients;  **Outcomes:** 37 of 334 cancer patients intubated and died; 314 of 5354 non-cancer patients intubated and 518 patients died |
| Montopoli et al [9] | Retrospective; multicenter | Italy | **Total number of COVID positive cancer patients**: 786  **Comparator:** 9280 non-cancer patients  **Study enrolment time period:** Data cut-off date: April 1 2020  **Male female ratio:**  For overall population, 4532 males and 4748 females  Cancer patients: 430 males and 356 females  **Outcomes assessed:** Mortality rate in male patients; Severe disease rates in male patients; Comparison of infection, mortality and severe disease rates between patients on ADT versus patients not on ADT  **Cancer subtypes:** Distribution described for males only; Prostate: 118; Genito-urinary: 73; Colorectal cancer: 65; Hematological: 47  **Outcomes:**  47.0% (n=2131) of male patients were hospitalized and 6.9% (n=312) died, while among patients with cancer 67.9% (n=292) were hospitalized and 17.4% (N=75) died. No significant differences were observed between prostate cancer patients and those affected by other types of cancers  **Treatment specific death rates:**  0 of 4 patients infected with COVID on ADT died; 18 of 114 (16%) prostate cancer patients not on ADT died |
| Moro et al [10] | Retrospective; single center | Spain | **Total number of COVID positive cancer patients**: 34 (Only Hematological malignancies)  **Comparator:** Single arm  **Study enrolment time period:** March 9 2020 to April 17 2020  **Median age:** 72.5 years (35- 94)  **Male female ratio:** 19 males; 15 females  **Co-morbidities:**  **Outcomes assessed:** Mortality rate  **Cancer subtypes:** Acute leukemia: 7; MDS: 3; CLL: 6; Lymphoma: 6; Plasma cell dyscrasia: 7  **Cancer Treatments:** Stem cell transplant: 3 patients  **Outcomes:** 11 (32%) of 34 died  **Cancer specific mortality rates:**  Acute leukemia: 4 of 7 (57%) patients died; MDS: 3 of 3 patients died; Plasma cell dyscrasia: 1 of 7 (14%) patients died; Myeloproliferative neoplasm: 3 of 5 (60%) patients died  **Treatment specific death rates:**  0 patients of stem cell transplant died |
| Robilotti et al [11] | Retrospective; single center | USA | **Total number of COVID positive cancer patients**: 423  **Comparator:** Single arm  **Study enrolment time period:** March 10 2020 to April 7 2020  **Male female ratio:** 212 males and 211 females  **Co-morbidities:** Hypertension: 214 (50%); Diabetes mellitus: 84 (20%); Asthma: 43 (10%); COPD: 29 (7%)  **Outcomes assessed:** Mortality rate; Assess risk factors for hospitalization and severe respiratory illness, defined as the requirement for high-flow oxygen supplementation or mechanical ventilation.  **Cancer subtypes:** Hematologic malignancies: 103 (25%); Breast: 86 (20%); Colorectal: 37 (9%); Lung: 35 (8%); Prostate: 26 (6%)  **Cancer Treatments:** Chemotherapy: 191 (45%); Immunotherapy: 31 (7%)  **Outcomes:**  Death: 39 of 423 (9%); Mechanical ventilation: 39 (9%). Severe illness was significantly more common with age > 65 years. Treatment with immunotherapy also remained an independent predictor of severe respiratory illness. Metastatic disease, recent receipt of chemotherapy, or major surgery within the previous 30 days did not show a significant association with either hospitalization or severe respiratory illness  **Cancer specific outcomes:**  Lung cancer severe illness: 15/ 35 (43%)  Others severe illness: 39/ 240 (16%)  **Treatment specific outcomes:**  Severe illness in immunotherapy: 12/ 31 (39%)  Severe illness in non-immunotherapy: 42/ 244 (17%) |
| Vuagnat et al [12] | Prospective; Cohort; Single center | France | **Total number of COVID positive cancer patients**: 59 (Only breast cancer)  **Comparator:** Single arm  **Study enrolment time period:** March 13 2020 to April 25 2020  **Median age:** 58 years (Range: 48 – 68)  **Co-morbidities:** Hypertension: 21 (36%); Diabetes mellitus: 10 (17%); Chronic lung disease: 2 (3%)  **Outcomes assessed:** Hospitalization rate; Mortality rate; Risk factors for death  **Cancer subtypes:** Only Breast cancer  **Cancer Treatments:** Surgery: 3 (5%); Chemotherapy: 29 (50%); Radiotherapy: 4 (7%); Endocrine therapy: 19 (32%); Targeted therapy: 13 (22%)  **Outcomes:**  Twenty-eight of these 59 patients (47%) were hospitalized and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (>70) were the two factors associated with a higher risk of intensive care unit admission and/or death  **Treatment specific death rates:**  No association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. |
| Wang et al [13] | Retrospective; multicenter | China | **Total number of COVID positive cancer patients**: 283  **Comparator:**  Single arm  **Study enrolment time period:** December 17, 2019 to 86 March 18, 2020  **Median age:** 63.0 years [IQR, 55.0 to 70.0]  **Male female ratio:** 1:1  **Co-morbidities:** The most common comorbidities were hypertension (33%), diabetes (14%), and cardiovascular disease (11%).  **Outcomes assessed:** Mortality rate; Assess risk factors for mortality  **Cancer subtypes:** 51 (18%) lung cancer, 38 (13%) breast cancer, and 34 (12%) colorectal cancer  **Cancer Treatments:** Of the 207 current cancer patients, 95 (46%) have received recent anti-tumor treatments, including 46 (22%) with chemotherapy, 23 (11%) with surgical resection, and 26 (13%) with other anti-tumor treatments.  **Outcomes:**  The overall mortality rate was 18% (50/283), and the median hospitalization stay for the survivors was 26 days. Amongst all, 76 (27%) were former cancer patients with curative resections for over five years without recurrence. The current cancer patients exhibited worse outcomes versus former cancer patients (overall survival, HR=2.45, 95%CI 1.10 to 5.44, log-rank 96 *p*=0.02; mortality rate, 21% vs 9%)  **Cancer specific mortality rates:**  Higher mortality rate observed in patients with lymphohematopoietic malignancies (LHM) (53%, 9/17). Multivariable analysis indicated that LHM (*p*=0.001) was one of the independent factors associating with critical 103 illness or death.  **Treatment specific death rates:**  The highest mortality rate observed in patients receiving recent chemotherapy (33%), followed by surgery (26%), other anti-tumor treatments (19%), and no anti-tumor treatment (15%). |
| Yang et al [14] | Retrospective; single center | China | **Total number of COVID positive cancer patients**: 52  **Comparator:** 1523 non cancer COVID patients  **Study enrolment time period:** January 1th to April 15th, 2020  **Median age**  63 years (range from 34 to 98 years)  **Male female ratio:** 28 males and 24 females  **Co-morbidities:** 33(63.5%) patients had comorbidities, the most common comorbidity was hypertension (17, 51.5%), followed by diabetes (7, 21.2%), coronary heart disease (5, 15.2%), cerebrovascular disease (4, 12.1%), chronic obstructive pulmonary disease (4, 12.1%), chronic hepatitis B (2, 6.1%), cirrhosis (1, 3.0%), chronic renal insufficiency (1, 3.0%) and hypothyroidism (1, 3.0%).  **Outcomes assessed:** Mortality rates;  **Cancer subtypes: L**ung cancer (19.2%), breast cancer (17.3%), rectal cancer (15.4%), colon cancer (9.6%), cervical cancer (7.7%) and thyroid carcinoma (5.8%**)**  **Cancer Treatments:** 10(19.2%) patients received anti-cancer treatment within one month. 6(11.5%) of them received chemotherapy, the remaining 4 patients received one therapy of catheter ablation, resection, pancreaticoduodenectomy, and immunotherapy respectively  **Outcomes:**  11 severe/critical patients died in this study,  **Cancer specific mortality rates:** 2 lung cancer, 2 breast cancer, 2 prostate cancer, 1 gastric cancer, I duodenal cancer, 1 endometrial cancer, 1 ovarian cancer, 1 lymphoma patients died  **Treatment specific death rates:**  2 of 11 received chemotherapy; 1 had undergone surgery |
| Zhang H et al [15] | Retrospective; multicenter | China | **Total number of COVID positive cancer patients**: 67  **Comparator:** Single arm  **Study enrolment time period:** Jan 5, 2020 to Feb 18, 2020  **Median age:** 66 years (range: 37-90)  **Male female ratio:** 41 males; 26 females  **Co-morbidities:** Forty-three (64.2%) patients had other concurrent  chronic diseases, of which hypertension (53.7%, n=36), diabetes (19.4%, n=13), and coronary heart disease (11.9%, n=8) were the most common  **Outcomes assessed:** Case fatality rate;  **Cancer subtypes:** Lung cancer (n=15, 22.4%) was the most common cancer type  **Cancer Treatments:** Twenty-three (34.3%) patient had received anticancer treatment recently; Among those 23 patients, 9 cases were receiving chemotherapy-based comprehensive therapies, 7 cases were during perioperative period, 3 cases were receiving supportive treatment, 2 cases were receiving radiotherapy combined with targeted therapy or with endocrine therapy, and the rest 2 patients were receiving endocrinotherapy or immunotherapy.  **Outcomes:**  18 (26.9%) patients died from COVID-19.  **Cancer specific mortality rates:**  Lung cancer accounted for the highest proportion COVID-19 resulted deaths (33.3%, 5/15). digestive system cancers (5/17, 29.4%) died; |
| Zhang L et al [16] | Retrospective; multicenter | China | **Total number of COVID positive cancer patients**: 28  **Comparator:** Single arm  **Study enrolment time period:** 13 January 2020 to 26 February 2020  **Median age:** 65 years (IQR: 56 – 70 years)  **Male female ratio:** 17 male; 11 female  **Co-morbidities:** Diabetes Mellitus: 4; Cardiovascular disease: 4  **Outcomes assessed:** Mortality rate; Severe event rate  **Cancer subtypes:** Lung cancer was the most frequent cancer type (n: 7; 25.0%); Esophageal cancer: 4; Breast cancer: 3; Head and neck: 3  **Cancer Treatments:** Surgery: 21 patients; Chemotherapy: 3; Radiotherapy: 1; immunotherapy: 1  **Outcomes:**  15 (53.6%) patients had severe events and the mortality rate was 28.6%. If the last anti-tumour treatment was within 14 days, it significantly increased the risk of developing severe events [hazard ratio (HR) 4.079, 95% confidence interval (CI)1.086-15.322, P: 0.037] |
| Stroppa et al [17] | Retrospective; single center | Italy | **Total number of COVID positive cancer patients**: 25  **Comparator:** 31 non cancer COVID patients  **Study enrolment time period:** 21 February 2020 and 18 March 2020  **Mean age:** Mean age of these patients was 71.64 years (range  50–84 years).  **Male female ratio:** 20 males; 5 females  **Co-morbidities:**  19 (76%), had several comorbidities (in particular diabetes mellitus  [32%], hypertension [64%] and chronic obstructive pulmonary disease [28%]).  **Outcomes assessed:** Mortality rate  **Cancer subtypes:**  The most common tumor site was lung (eight patients, 32%) followed by gastroenteric tumor (six patients, 24%), genitourinary tumor (six patients, 24%), breast cancer (two patients, 8%), hematologic tumor (two patients, 8%) and undefined tumor site (one patient, 4%).  **Cancer Treatments:**  12 (48%) patients were treated with anticancer therapy: eight (66.67%) with chemotherapy and four (33.33%) with immunotherapy  **Outcomes:**  9 of 25 patients died  **Cancer specific mortality rates:** 2 breast cancer patients, 3 genito-urinary patients, 2 hematological malignancy patients, 2 lung cancer patients died |
| Basse et al[18] | Retrospective; single center | France | **Total number of COVID positive cancer patients**: 141  **Comparator:** 9701 non- COVID cancer patients  **Study enrolment time period:** March 13 2020 to April 25 2020  **Median age:** 62 years  **Male female ratio:** Females: 102; Males: 39  **Co-morbidities:** Hypertension (34%) and diabetes (17%).  **Outcomes assessed:** Mortality rates  **Cancer subtypes:** Breast cancer was the most common cancer type (40%), followed by lung cancer (13%), haematological malignancies (13%), gynaecological cancers (9%)  **Outcomes:**  26 patients (18%) had died from COVID-19  **Cancer specific mortality rates:**  Lung cancers had the worst outcome (n=6 i.e. 23% of all deaths) followed by haematological malignancies (n=5, 19%), breast (n=5, 19%) and gynaecological cancers (n=2, 7%). |
| Russels et al [19] | Retrospective; single center | UK | **Total number of COVID positive cancer patients**: 106  **Comparator:** Single arm  **Study enrolment time period:** 29 February 2020-15 April 2020.  **Median age:** 67 years  **Male female ratio:** 58 males; 48 females  **Co-morbidities:** Hypertension was the most commonly reported comorbidity (51%), followed by diabetes mellitus (22%), renal impairment (22%) and cardiovascular disease (20%)  **Outcomes assessed:** Mortality rate; Factors associated with mortality  **Cancer subtypes:** The most frequently reported tumour types were urological/gynaecological (34%), followed by haematological (18%) and breast (15%)  **Outcomes:**  14 cancer patients died of COVID-19 (13%) |
| Kabaritti et al[20] | Retrospective; single center | USA | **Total number of COVID positive cancer patients**: 107  **Comparator:** Single arm  **Study enrolment time period:** March 14 2020 and April 15 2020  **Median age**  **Male female ratio:** 53 males; 54 females  **Outcomes assessed:** Mortality rate; Risk factors for mortality  **Cancer subtypes:** Breast cancer: 28; Prostate cancer: 27; Lung cancer: 14  **Outcomes:**  24 patients died  **Cancer specific mortality rates:**  Lung cancer diagnosis was also associated with increased risk of death (HR=2.96, 95% CI: 1.09 to 9.27, p=0.034).  **Treatment specific death rates:**  Cox proportional hazards models demonstrated a significant association between mean radiotherapy dose delivered to the lungs and risk of death (HR=1.12 per Gy, 95% CI: 1.04 to 1.20, p=0.002). |
| Deng et al[21] | Retrospective; Database | China | **Total number of COVID positive cancer patients**: 107  **Comparator:** 44565 non-cancer COVID patients  **Study enrolment time period:** Data cut-off February 11 2020  **Outcomes:**  6 cancer patients died (5.6%)  Overall mortality rate: 2.3% |
| Ma et al [22] | Retrospective; single center | China | **Total number of COVID positive cancer patients**: 37  **Comparator:** Single arm  **Study enrolment time period:** January 1, 2020 to March 30, 2020  **Median age:** 62 years  **Male female ratio:** 20 males; 17 females  **Outcomes assessed:** Mortality rates; Severe infection rate  **Cancer subtypes:** most common cancer was colorectal  cancer (29.7%), followed by lung cancer (21.6%) and breast (18.9%).  **Outcomes:**  5 (13.5%) cancer patients died |
| Cook et al [23] | Retrospective | UK | **Total number of COVID positive cancer patients**: 75 (Only multiple myeloma)  **Comparator:** Single arm  **Study enrolment time period:** Data cut off: 18 May 2020  **Median age:** 73 years (range 47-88)  **Co-morbidities:** Hypertension was the commonest comorbidity (41.3% of patients)  **Outcomes assessed:** Mortality rate; Hospital stay; Time to discharge  **Outcomes:**  41 patients died |
| Kalinsky et al [24] | Retrospective | USA | **Total number of COVID positive cancer patients**: 27 (Only Breast cancer)  **Comparator:** Single arm  **Study enrolment time period:** 10 March 2020 to 29 April 2020  **Median age:** 56 years (range: 32–87)  **Male female ratio:** 26 females; 1 male  **Co-morbidities:** Co-morbidities included 15 (56%) with hypertension, 6 (22%) diabetes, and 6 (22%) pulmonary disease.  **Outcomes assessed:** Mortality rate; Treatment disruption rate  **Cancer Treatments:**  16 (59%) received chemotherapy, 12 (44%) hormone therapy, 6 (22%) HER2-directed therapy, 1 (4%) checkpoint inhibitor, 6 (22%) breast surgery, and 2 (7%) radiation therapy  **Outcomes:**  1 of 27 patients died |
| Cao et al [25] | Retrospective | Spain | **Total number of COVID positive cancer patients**: 50 (Only melanoma)  **Comparator:** Single arm  **Study enrolment time period:** April 1 2020 to May 17 2020  **Median age:** 69 years (range 6 to 94 years),  **Male female ratio:** 27 (54%) patients are males; 23 (46%) are females  **Outcomes assessed:** Mortality rates  **Cancer Treatments:** Twenty-two (44%) patients were on active anticancer treatment with anti PD-1 antibodies, 16 (32%) patients were on treatment with BRAF plus MEK inhibitors and 12 (24%) patients were not on active cancer treatment  **Outcomes:**  9 patients died from COVID  **Treatment specific death rates:**  Mortality rates from COVID-19 according to melanoma treatment type were 16%, 15% and 36% for patients on immunotherapy, targeted drugs, and for those that were not undergoing active cancer treatment, respectively |
| Fratino et al [26] | Database retrospective multicenter | Italy | **Total number of COVID positive cancer patients**: 20534  **Comparator:** Two arms  **Study enrolment time period:** Till March 30 2020  **Median age:** Median 80.0, Inter Quartile Range—IQR 75.0– 85.8)  **Outcomes assessed:** Mortality rates  150/20534 patients died of COVID disease |

**References**

1. Dai M, Liu D, Liu M et al. Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020.

2. He W, Chen L, Chen L et al. COVID-19 in persons with haematological cancers. Leukemia 2020; 1-9.

3. Joharatnam-Hogan N, Hochhauser D, Shiu K-K et al. Outcomes of the 2019 Novel Coronavirus in patients with or without a history of cancer - a multi-centre North London experience. 2020; 2020.2004.2016.20061127.

4. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020.

5. Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337.

6. Luo J, Rizvi H, Egger JV et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov 2020.

7. Mehta V, Goel S, Kabarriti R et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. 2020; CD-20-0516.

8. Miyashita H, Mikami T, Chopra N et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020.

9. Montopoli M, Zumerle S, Vettor R et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Ann Oncol 2020.

10. Martín-Moro F, Marquet J, Piris M et al. Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies. Br J Haematol 2020.

11. Robilotti EV, Babady NE, Mead PA et al. Determinants of Severity in Cancer Patients with COVID-19 Illness. 2020; 2020.2005.2004.20086322.

12. Vuagnat P, Frelaut M, Ramtohul T et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. 2020; 2020.2004.2030.20085928.

13. Wang J, Song Q, Chen Y et al. Systematic investigations of COVID-19 in 283 cancer patients. 2020; 2020.2004.2028.20083246.

14. Yang F, Shi S, Zhu J et al. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020.

15. Zhang H-Y, Wang L-W, Chen Y-Y et al. A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan, China. 2020; 2020.2003.2021.20037127.

16. Zhang L, Zhu F, Xie L et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020.

17. Stroppa EM, Toscani I, Citterio C et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol 2020.

18. Basse C, Diakite S, Servois V et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. 2020; 2020.2005.2014.20101576.

19. Russell B, Moss C, Papa S et al. Factors affecting COVID-19 outcomes in cancer patients − A first report from Guys Cancer Centre in London. 2020; 2020.2005.2012.20094219.

20. Rafi Kabarriti NPB, Maxim I. Maron, Wolfgang A. Tomé, Balazs Halmos, Chandan Guha, Shalom Kalnicki, Madhur K. Garg, Nitin Ohri, . Extent of prior lung irradiation and mortality in COVID-19 patients with a cancer history. Advances in Radiation Oncology 2020.

21. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care 2020; 24: 179.

22. Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study. J Infect 2020.

23. Cook G, Ashcroft AJ, Pratt G et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy. n/a.

24. Kalinsky K, Accordino MK, Hosi K et al. Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast Cancer Res Treat 2020; 1-4.

25. Cao B, Wang Y, Wen D et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. 2020; 382: 1787-1799.

26. Fratino L, Procopio G, Di Maio M et al. Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic. Front Oncol 2020; 10: 648.